Assessment of new therapies for infection due to the Mycobacterium avium complex: Appropriate use of in vitro and in vivo testing

Jacques H. Grosset

Research output: Contribution to journalArticle

Abstract

Laboratory testing is a prerequisite to predictions about the potential value of human clinical trials-the gold standard for the assessment of new therapies for infection with the Mycobacterium avium complex (MAC). These laboratory assessments must be made in the proper sequence, with appropriate models and methodology used to obtain data valid in determining whether clinical trials are warranted. In vitro testing permits measurements of minimal inhibitory and minimal bactericidal concentrations, identification of the synergism or antagonism of various agents, definition of an agent's pharmacokinetic properties (e.g., hydrophilicity or lipophilicity), and evaluation of a drug's intracellular penetration and activity against intracellular organisms. The most appropriate animal model for in vivo testing of activity against MAC is the beige mouse. Experiments in this model provide important data on an agent's minimal effective dose and on its optimal dose, dosing frequency, and route(s) of administration. Evaluations in the beige mouse also document whether the agent is bactericidal or bacteriostatic, whether it selects drug-resistant mutants, and whether its use in combination with other agents is beneficial.

Original languageEnglish (US)
JournalClinical Infectious Diseases
Volume18
Issue numberSUPPL. 3
StatePublished - Apr 1994
Externally publishedYes

Fingerprint

Mycobacterium avium Complex
Clinical Trials
Drug Evaluation
Infection
Hydrophobic and Hydrophilic Interactions
Animal Models
Pharmacokinetics
Therapeutics
Pharmaceutical Preparations
In Vitro Techniques

ASJC Scopus subject areas

  • Immunology

Cite this

Assessment of new therapies for infection due to the Mycobacterium avium complex : Appropriate use of in vitro and in vivo testing. / Grosset, Jacques H.

In: Clinical Infectious Diseases, Vol. 18, No. SUPPL. 3, 04.1994.

Research output: Contribution to journalArticle

@article{0486aad06cb74b0189405d79a68781ec,
title = "Assessment of new therapies for infection due to the Mycobacterium avium complex: Appropriate use of in vitro and in vivo testing",
abstract = "Laboratory testing is a prerequisite to predictions about the potential value of human clinical trials-the gold standard for the assessment of new therapies for infection with the Mycobacterium avium complex (MAC). These laboratory assessments must be made in the proper sequence, with appropriate models and methodology used to obtain data valid in determining whether clinical trials are warranted. In vitro testing permits measurements of minimal inhibitory and minimal bactericidal concentrations, identification of the synergism or antagonism of various agents, definition of an agent's pharmacokinetic properties (e.g., hydrophilicity or lipophilicity), and evaluation of a drug's intracellular penetration and activity against intracellular organisms. The most appropriate animal model for in vivo testing of activity against MAC is the beige mouse. Experiments in this model provide important data on an agent's minimal effective dose and on its optimal dose, dosing frequency, and route(s) of administration. Evaluations in the beige mouse also document whether the agent is bactericidal or bacteriostatic, whether it selects drug-resistant mutants, and whether its use in combination with other agents is beneficial.",
author = "Grosset, {Jacques H.}",
year = "1994",
month = "4",
language = "English (US)",
volume = "18",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Assessment of new therapies for infection due to the Mycobacterium avium complex

T2 - Appropriate use of in vitro and in vivo testing

AU - Grosset, Jacques H.

PY - 1994/4

Y1 - 1994/4

N2 - Laboratory testing is a prerequisite to predictions about the potential value of human clinical trials-the gold standard for the assessment of new therapies for infection with the Mycobacterium avium complex (MAC). These laboratory assessments must be made in the proper sequence, with appropriate models and methodology used to obtain data valid in determining whether clinical trials are warranted. In vitro testing permits measurements of minimal inhibitory and minimal bactericidal concentrations, identification of the synergism or antagonism of various agents, definition of an agent's pharmacokinetic properties (e.g., hydrophilicity or lipophilicity), and evaluation of a drug's intracellular penetration and activity against intracellular organisms. The most appropriate animal model for in vivo testing of activity against MAC is the beige mouse. Experiments in this model provide important data on an agent's minimal effective dose and on its optimal dose, dosing frequency, and route(s) of administration. Evaluations in the beige mouse also document whether the agent is bactericidal or bacteriostatic, whether it selects drug-resistant mutants, and whether its use in combination with other agents is beneficial.

AB - Laboratory testing is a prerequisite to predictions about the potential value of human clinical trials-the gold standard for the assessment of new therapies for infection with the Mycobacterium avium complex (MAC). These laboratory assessments must be made in the proper sequence, with appropriate models and methodology used to obtain data valid in determining whether clinical trials are warranted. In vitro testing permits measurements of minimal inhibitory and minimal bactericidal concentrations, identification of the synergism or antagonism of various agents, definition of an agent's pharmacokinetic properties (e.g., hydrophilicity or lipophilicity), and evaluation of a drug's intracellular penetration and activity against intracellular organisms. The most appropriate animal model for in vivo testing of activity against MAC is the beige mouse. Experiments in this model provide important data on an agent's minimal effective dose and on its optimal dose, dosing frequency, and route(s) of administration. Evaluations in the beige mouse also document whether the agent is bactericidal or bacteriostatic, whether it selects drug-resistant mutants, and whether its use in combination with other agents is beneficial.

UR - http://www.scopus.com/inward/record.url?scp=0028204933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028204933&partnerID=8YFLogxK

M3 - Article

C2 - 8204775

AN - SCOPUS:0028204933

VL - 18

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - SUPPL. 3

ER -